固定されたツイート
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh8K…
English
cafepharma
74K posts
cafepharma
@cafepharma
The original site for employees in pharma, medical & diagnostic sales. Pharma & biotech news with context, clarity, and a little industry humor.
Atlanta 参加日 Ağustos 2008
295 フォロー中17.5K フォロワー
Fri news: Starting material sourcing bottlenecks increase US drug shortage risks. Stryker operations fully restored after cyberattack. Novartis cuts 114 more jobs at New Jersey HQ. Jury orders Abbott to pay $53M in preterm infant formula trial. —bit.ly/3JeBlY5
English
Thurs news: Lilly launches oral GLP-1, kicking off showdown with Novo. Takeda’s ITP drug triggers up to 91% resp rate. AbbVie files lawsuit to address ‘outdated’ drug discount program. How medtech companies are coping with tariffs, one year in. —bit.ly/3JeBlY5
English
Wed news: Pfizer walks away from San Fran office space. Biogen settles investor lawsuit. Merck’s original Tern’s offer was higher. Hologic hires former Baxter leader as CEO. —bit.ly/3JeBlY5
English
Tue news: Pfizer breast cancer prospect delivers phase 2 win. Sarepta to start gene therapy safety enhancement study. FDA accepts Sun Pharmaceuticals psoriatic arthritis sBLA. Middle East conflict disrupts pharma supplies —bit.ly/3JeBlY5
English
Mon news: Meds from Amgen and GSK now offered through TrumpRx. Novo regained weight loss footing, but Lilly is coming. Abivax denies report of AstraZeneca takeover. AZ piles pressure on Merck in gastric cancer. —bit.ly/3JeBlY5
English
Fri news: Eliquis safer than Xarelto for patients with deep clots. Ipsen appoints new President of North America. Lilly spending $$ on Japanese manufacturing expansion. Ultragenyx gene therapy phase 3 win. —bit.ly/3JeBlY5
English
Mon news: Novo deal for Hims to sell Wegovy and Ozempic. AbbVie amylin bet demonstrates almost 10% weight loss in 12 weeks. Roche oral SERD flunks phase 3 breast cancer trial. Vinay Prasad departing FDA. —bit.ly/3JeBlY5
English